Table 3 Patient characteristics and the incidence of SSI
From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery
Patient characteristics | SSI− (n = 269) | SSI+ (n = 12) | P value |
|---|---|---|---|
Mean age (range) | 72.9 ± 10.6 | 77.4 ± 11.3 | 0.151 |
Gender | 0.37 | ||
M | 155 (57.6%) | 9 (75.0%) | |
F | 114 (42.4%) | 3 (25.0%) | |
Mean BMI ± SD | 22.2 ± 3.5 | 22.9 ± 3.9 | 0.485 |
Diabetes mellitus (%) | 78 (29.0%) | 7 (58.3%) | 0.0489 |
Albumin ± SD | 3.89 ± 0.53 | 3.71 ± 0.52 | 0.244 |
Respiratory disease | 43 (16.0%) | 4 (33.3%) | 0.122 |
Anticoagulant | 28 (17.1%) | 5 (45.5%) | 0.032 |
ASA | 0.0434 | ||
1.2 | 207 (77.0%) | 6 (50.0%) | |
3 | 62 (23.0%) | 6 (50.0%) | |
Mean operation time ± SD | 300.1 ± 110.0 | 339.7 ± 191.8 | 0.242 |
Bleeding (ml) | 128.4 ± 222.6 | 188.6 ± 340.0 | 0.373 |
Approach | 1 | ||
Open | 127 (50.0%) | 6 (50.0%) | |
Laparoscopy | 127 (50.0%) | 6 (50.0%) | |
Transfusion | 6 (2.2%) | 0 (0%) | 1 |
Use of olanexidine | 217 (90.4%) | 6 (50.0%) | 0.02 |
Primary lesion | 0.118 | ||
Stomach | 82 (34.2%) | 1 (8.3%) | |
Colon | 187 (65.8%) | 11 (91.7%) | |
Tumor size (cm) | 4.65 ± 2.56 | 4.25 ± 2.13 | 0.595 |
Stage | 0.543 | ||
0, I, II | 180 (66.9%) | 7 (58.3%) | |
III, IV | 89 (33.1%) | 5 (41.7%) | |
Leakage | 9 (100%) | 0 (0%) | 1 |
Complication except SSI | 63 (23.5%) | 6 (50.0%) | 0.0782 |
Adverse skin reaction (all) | 7 (2.6%) | 0 (0%) | 1 |